amphipathic peptides. Some of the primary amphipathic CPPs are chimeric peptides which bind to the nuclear localization sequences (NLS) via covalent bonds for effective penetration through the cell membranes. MPG is based on the NLS sequence of SV40 and HIV gp41 protein.
In MPG, the hydrophobic region is separated from NLS with a linker [11] .
Recently, a new cysteine-rich cationic CPP, called CyLoP-1, has been developed for the delivery of peptide and protein cargoes. CyLoP-1 was derived from the nuclear localization sequence of a snake toxin, called crotamine [12] . The presence of cysteine and tryptophan amino acids is necessary to maintain its function. Besides, the cysteine oxidation status plays an essential role in the uptake efficiency of CyLoP-1, and the disulfide-containing form plays a more active role in the CyLoP-1 uptake efficiency [13] .
In this study, our goal was to produce Nef protein in a prokaryotic expression system as a candidate HIV-1 vaccine and its delivery into HEK-293T cells using two novel cell-penetrating peptides.
MATERIAL AND METHODS
Expression and purification of HIV-1 Nef protein. The pET-23a (+) prokaryotic expression vector (Novagen, USA) harboring HIV-1 Nef protein has been previously prepared by our group [14] . To produce the Nef protein, Escherichia coli Rosetta strain was transformed with pET23a (+) harboring the nef gene. The recombinant clones were selected on LB (Luria-Bertani) agar (Sigma-Aldrich, Germany) containing ampicillin and transferred to Ty2x medium to an optical density of 0.7-0.8 at a wavelength of 600 nm. Then, 1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG, SINACON, Iran) was used at 37°C to induce the expression of the Nef protein. The cell pellet was collected, and the protein expression was analyzed by SDS-PAGE in a gel containing 12.5% acrylamide and western blot using an anti-His tag antibody (Abcam, USA). Nef protein was purified by affinity chromatography using Ni-NTA agarose column (MachereyNagel) under native conditions (i.e., 250 mM imidazole buffer, pH=8). The concentration and purification of Nef were measured by the Bradford protein assay kit (Thermo Fisher Scientific) and NanoDrop spectrophotometer (Thermo Fisher Scientific). The expression of the recombinant (r) Nef protein was analyzed by western blot using an anti-His tag antibody (Abcam, USA).
Preparation of the CPP/Nef DNA and CPP/Nef protein complexes. The CyLoP-1 (CRWRWKCCKK) and MPG (GALFLGFLGAAGSTMGAWSQPKKKRKV) peptides were synthesized by Biomatik Corporation (Cambridge, Canada). The pEGFP-N1 eukaryotic expression vector (Clontech, USA) harboring Nef protein has been previously prepared by our group [14] . To form the MPG/pEGFP-N1-nef complexes, different concentrations of MPG were mixed with 2 μg of pEGFP-N1-nef at N/P (nitrogen to phosphate) ratios of 1, 2, 5 and 10, and incubated at room temperature for 45 min. The formation of the MPG/pEGFP-N1-nef complexes was investigated by gel retardation assay. DNase I was added to the complexes with different N/P ratios of 1, 2, 5 and 10, and incubated at 37°C for 1 h to verify the stability of MPG/DNA complexes against DNA nucleases. For the evaluation of serum stability, the complexes with N/P ratio of 10 were exposed to 10% serum at 37°C for 5 h [15] . To form the CyLoP-1/Nef complexes, different concentrations of CyLoP-1 were mixed with 1 μg of Nef protein at CyLoP-1:Nef molar ratios of 2:1, 5:1, 10:1, 15:1, 20:1, 30:1, and incubated for 60 min at room temperature. The formation of the CyLoP-1/Nef complexes was confirmed by SDS-PAGE in a 12.5% acrylamide gel.
SEM and Zetasizer studies. The MPG/pEGFP-N1-nef and CyLoP-1/Nef nanoparticles were formed with a ratio of 10, and their size and morphology were determined using a scanning electron microscope (SEM) (FEI Quanta 200 SEM, PHILIPS, USA). The charge of nanoparticles was assessed by Zetasizer Nano ZS (Malvern Instruments, UK) at 25°C.
MTT assay. The viability of the cells treated with complexes was assessed by MTT assay. Human embryonic kidney cells (HEK-293T, CRL-1651, Pasteur Institute of Iran; 1×10 4 cells/ well) were seeded in a 96-well plate (Greiner, Germany), and cultured in RPMI-1640 medium (Sigma, Germany) supplemented with 5% FBS (Fetal Bovine Serum, Gibco, Germany) and 1% Gentamicin solution at 37°C and 5% CO2 for 24 h. The medium was replaced by fresh RPMI-1640. The MPG, pEGFP-N1-nef, MPG/pEGFP-N1-nef (N/P ratio of 10), CyLoP-1, rNef protein and CyLoP-1/Nef (molar ratio of 10) were added to the cells and cultured for 48 h. Then, the medium was removed, and the MTT solution (5 mg/mL, Sigma) was added to each well and incubated for 3 h at 37°C. After adding Dimethyl Sulfoxide (DMSO, Sigma, Germany) to each well, the absorbance was measured by ELISA reader at a wavelength of 570 nm. Untreated cells and cells treated with 70% ethanol were considered as negative and positive controls, respectively.
Transfection of HEK-293T cells with the Nef nanoparticles. HEK-293T cells (5×10
4 cells/well) were seeded in a 24-well plate (Greiner, Germany), followed by incubation for 24 h. The MPG/pEGFP-N1-nef complexes were prepared with the N/P ratio of 10. Then, the medium was removed, the complexes were added to cells, and the cells were incubated at 37°C for 6 h. Then, the medium was replaced with complete RPMI-1640 medium supplemented with 5% FBS, and the cells were incubated at 37°C for 48 h. The cells treated with TurboFect (Fermentas)/pEGFP-N1-nef complexes were considered as positive control, and the untreated cells were considered as negative control. The transfection efficiency of the cells treated with the complexes was evaluated by fluorescence microscopy (Envert Fluorescent Ceti, Korea) and FACS Calibur flow cytometer (Partec, Germany). Also, the expression of the Nef protein was evaluated by western blot analysis (Abcam, USA). The CyLoP-1/Nef complexes were prepared at a molar ratio of 10:1. Then, the medium was removed, and the complexes were added to cells. After incubation of cells at 37°C for 2 h, the cells were treated with trypsin-EDTA and harvested by centrifugation. The cells treated with TurboFect (ProJect, Fermentas)/Nef complexes were considered as positive control and the untreated cells as negative control. The transfection efficiency of the cells treated with complexes was evaluated by western blot using an anti-His-tag antibody (Abcam, USA).
Statistical analysis. Prism 5.0 software (GraphPad, San Diego, California, USA) was used for statistical analysis (Student's t-test) of cell viability and cell transfection. The value of p<0.05 was considered statistically significant. Each experiment was repeated two times.
RESULTS
Expression and purification of HIV-1 Nef protein. The expression of Nef protein was evaluated in Rosetta strain. The optimal expression of Nef was observed at 37°C Downloaded from jommid.pasteur.ac.ir at 15:14 IRST on Tuesday January 28th 2020 2019 Vol. 7 No. 1-2 and 16 h of induction. The results showed that Nef could be purified successfully under native conditions. The Nef was observed as a bright band of ~30 kDa in SDS-PAGE gel containing 12.5% acrylamide (Fig. 1) . The purified Nef protein was detected and confirmed by western blot using an anti-His-tag antibody. The concentration of the recombinant peptide was between 0.6-0.8 mg/mL. According to LAL assay, contamination with LPS was less than 0.5 EU/mg (QCL-1000, Lonza).
Formation of the HIV-1 Nef nanoparticles. The MPG/pEGFP-N1-nef complexes were prepared with the N/P ratios of 1, 2, 5 and 10, and loaded in 1% agarose gel. The results of the gel retardation assay showed that DNA did not migrate in agarose gel at N/P ratio of 10 indicating the formation of MPG/pEGFP-N1-nef complexes (Fig. 2) . After treatment with DNase I and serum, pEGFP-N1-nef (control) was degraded rapidly, while DNA in the MPG/pEGFP-N1-nef complexes with N/P ratio of 10 remained intact. The formation of CyLoP-1/Nef complexes was confirmed by SDS-PAGE analysis. The CyLoP-1/Nef complexes were observed as two separate bands of ~30 kDa (Nef) and ~1.4 kDa (CyLoP-1) in SDS-PAGE containing 12.5% acrylamide. This data indicated the non-covalent interactions between rNef and CyLoP-1 at 1:2, 1:5, 1:10, 1:15, 1:20 and 1:30 molar ratios (Fig. 3) .
SEM and Zetasizer studies. The size and morphology of nanoparticles were studied by SEM. The pEGFP-N1-nef (Fig. 4a) and MPG (Fig. 4b) formed spherical MPG/pEGFP-N1-nef complexes (N/P ratio: 10) with an average diameter of 100-200 nm (Fig. 4c) . The rNef protein (Fig. 4d) and CyLoP-1 (Fig. 4e) formed non-spherical CyLoP-1/Nef complexes (molar ratio of 10:1) with an average diameter of 100-150 nm (Fig. 4f) . The charge of complexes was studied by Zetasizer at the same ratios ( Table 1 ). The pEGFP-N1-nef (-9.27 mV) and rNef (-24.9 mV) had negative charges, while the MPG/pEGFP-N1-nef (+23.2 mV) and CyLoP-1/Nef (+4.35 mV) complexes had positive charges.
Cytotoxicity assay. Cell viability results showed that MPG, pEGFP-N1-nef, MPG/pEGFP-N1-nef, CyLoP-1, rNef protein, and CyLoP-1/rNef had no significant cytotoxicity on the cells within 48 h (p>0.05; Fig. 5 ).
Cell transfection with the nanoparticles. Transfection of HEK-293T cells with MPG/pEGFP-N1-nef (N/P: 10) complexes was evaluated 48 h after transfection using fluorescence microscopy, flow cytometry, and western blot analysis. The results showed that MPG was able to deliver pEGFP-N1-nef into the cells, which led to the expression of Nef protein in the cells. The transfected cells appeared as green spots in the fluorescent microscopy images (Fig. 6) . Flow cytometry exhibited that the cellular uptake of TurboFect/pEGFP-N1-nef and MPG/pEGFP-N1-nef complexes were 73.71 ± 091 % and 28.60 ± 2.06%, respectively (p<0.05; Fig. 6 ). Moreover, the expression of Nef protein in the cells was confirmed by western blot analysis using an anti-His-tag antibody. Nef protein was observed as a clear band of ~30 kDa in the cells treated with the complexes. No bands were observed in untreated cells. Transfection of HEK-293T cells with the CyLoP-1/Nef complexes (molar ratio of 10) was evaluated 2 h after transfection by western blot analysis using an anti-His-tag antibody. The results showed that CyLoP-1 was able to deliver rNef protein into the cells 2 h after transfection and HIV-1 Nef was observed as a clear band of ~30 kDa in the cells treated with the complexes. No bands were observed in the untreated cells (Fig. 7) . [16] . The Gp120-, Gp160-and Tat-based vaccines are among the developed protein vaccines, but they are not efficient enough in stimulating the HIV-specific responses [17] . Some studies focused on Nef regulatory protein which is highly conserved and immunogenic [18] . Nef is an essential factor in the pathogenesis of the HIV-1 virus [19] . The most critical weakness of protein vaccines is their low immunogenicity [20] . Some methods such as the use of carriers (e.g., CPPs) were developed to overcome this problem [16] . In this study, we used CPPs to deliver HIV-1 Nef protein and DNA into HEK-293T cells. The MPG peptide was used to transfer pEGFP-N1-nef into the cells [21] . Gros and colleagues (2006) studied non-covalent interactions between MPG and the plasmid DNA and showed that there is a high affinity between CPP and charged molecules [22] . In another study, Simeoni (2003) demonstrated that MPG is 80-95% efficient in delivery of luciferase gene [23] . In the present study, MPG/pEGFP-N1-nef complexes (N/P: 10) formed nanoparticles with a diameter of < 200 nm. Moreover, Zetasizer results indicated that the combination of negatively charged pEGFP-N1-nef with positively charged MPG peptides forms positively charged complexes that could pass through plasma membrane. Karjoo and colleagues (2013) suggested that nanoparticles with positive charges and a diameter of about 200 nm can pass through the membrane [24] . Our SEM results indicated that MPG/pEGFP-N1-nef complexes are spherical. Yoo and colleagues (2011) reported that spherical nanoparticles were delivered more efficiently than non-spherical nanoparticles [25] . In the present study, Fluorescence microscopy and flow cytometry results demonstrated that the transfection efficiency of the MPG/pEGFP-N1-nef nanoparticles (~ 28.60%) was less than TurboFect/pEGFP-N1-nef complexes (~ 73.71%). Some studies have indicated that the transfection efficiency of CPPs depends on the transfection conditions, CPP and cargo features, and cell type [26] . Our MTT assay results showed that MPG, pEGFP-N1-nef and the MPG/pEGFP-N1-nef nanoparticles (N/P: 10) had no significant toxicity for the cells, and hence, can be used in vivo. Moreover, we used CyLoP-1 to deliver the Nef protein into HEK-293T cells. Cysteine-rich peptides like CyLoP-1 were previously used to deliver biomolecules into cells [27] . The particles with positive charges can interact with the negatively charged membrane and cause the membrane lysis [28] . Sabouri-Rad and colleagues (2017) demonstrated that CyLoP-1 could increase transfection and decrease cell cytotoxicity [29] . In our study, CyLoP-1 was able to transfer the Nef protein into HEK-293T cells. The CyLoP-1/Nef (molar ratio of 10:1) complexes formed stable nanoparticles with a diameter of <200 nm. The SEM results showed that CyLoP-1/Nef complexes were spherical. Zetasizer results showed that the combination of negatively charged Nef protein with the positively charged CyLoP-1 peptide formed positively charged complexes that could pass through the plasma membrane. Western blot results indicated that CyLoP-1, similar to TurboFect, could deliver the Nef protein into the cells. MTT assay results showed that CyLoP-1, Nef protein and the CyLoP-1/Nef nanoparticles (molar ratio of 10:1) had no significant toxicity for the cells, and can be used in vivo assay.
In conclusion, CyLoP-1 and MPG peptides formed stable non-covalent complexes with rNef protein and pEGFP-N1-nef, respectively. They were able to deliver these nanoparticles into HEK-293T cells. Also, MTT results showed that these nanoparticles do not have significant toxicity in specific doses. However, further studies are needed to evaluate the delivery of pEGFP-N1-nef and Nef protein in vivo.
